Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program

BACKGROUND: Onartuzumab, a recombinant humanized monovalent monoclonal antibody directed against MET, the receptor for the hepatocyte growth factor, has been investigated for the treatment of solid tumors. This publication describes the safety profile of onartuzumab in patients with solid tumors usi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:PLoS One
Egile Nagusiak: Morley, Roland, Cardenas, Alison, Hawkins, Peter, Suzuki, Yasuyo, Paton, Virginia, Phan, See-Chun, Merchant, Mark, Hsu, Jessie, Yu, Wei, Xia, Qi, Koralek, Daniel, Luhn, Patricia, Aldairy, Wassim
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Public Library of Science 2015
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4596876/
https://ncbi.nlm.nih.gov/pubmed/26445503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0139679
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak